Substituted bicyclic methyl azetidines as sphingosine-1 phosphate receptors modulators

A compound having Formula I, its individual enantiomers, individual diastereoisomers, and individual isomers, individual tautomers or a pharmaceutically acceptable salt thereof

• wherein:
• represents a single bond,
• or a double bond
• represents a single bond,
• or a double bond
• or a triple bond
• A is substituted or unsubstituted C6-10 aryl, substituted or unsubstituted heterocycle, substituted or unsubstituted C5-8 cycloalkyl, substituted or unsubstituted C5-8 cycloalkenyl, or hydrogen;
• R2 is hydrogen, halogen, —OC1-3 alkyl, substituted or unsubstituted C1-3 alkyl, CN, C(O)R7, NR8R9 or hydroxyl;
• R3 is OPO3H2, carboxylic acid, PO3H2, substituted or unsubstituted C1-6 alkyl, —S(O)2H, —P(O)MeOH, —P(O)(H)OH or OR10;
• R4 is hydrogen, halogen, —OC1-3 alkyl, substituted or unsubstituted C1-3 alkyl, CN, C(O)R7, NR8R9 or hydroxyl;
• R5 is hydrogen, halogen, —OC1-3 alkyl, substituted or unsubstituted C1-3 alkyl, CN, C(O)R7, NR8R9 or hydroxyl;
• R6 is hydrogen, halogen, —OC1-3 alkyl, substituted or unsubstituted C1-3 alkyl, CN, C(O)R7, NR8R9 or hydroxyl;
• R7 is hydrogen, OR10 or substituted or unsubstituted C1-3 alkyl;
• R8 is hydrogen or substituted or unsubstituted C1-3 alkyl;
• R9 is hydrogen or substituted or unsubstituted C1-3 alkyl;
• R10 is hydrogen or substituted or unsubstituted C1-3 alkyl;
• L1 is O, S, NH or CH2;
• L2 is O, S, NH, a direct bond or CH2;
• a is 0 or 1;
• b is 0, 1, 2 or 3;
• c is 0, 1, 2 or 3;
• d is 0, 1, 2 or 3;
• with the provisos
• when a is 1 then
• represents
• or
• or
• or
• or
• or
• and
• when a is 0 then R1 is O, S, NH, or CH2.